ImmunityBio (IBRX) shares plummeted 22.4% today following a warning letter from the FDA, which criticized a television advertisement and comments from Dr. Patrick Soon-Shiong as “false and misleading.” This marks a troubling trend for the company, as the FDA had previously issued similar warnings regarding its oncology drug Anktiva® in September and January, highlighting ongoing concerns about overstated efficacy claims that have not been substantiated by clinical trials.

This development is significant for ImmunityBio and the broader biopharma sector, as it raises serious questions about the company’s credibility and the future of its ongoing clinical trials. While Anktiva has received approval for a limited patient population, the FDA’s scrutiny could undermine investor confidence and impact stock performance, especially given the company’s ambitious pipeline of 12 other trials.

For market professionals, the key takeaway is the increased volatility surrounding ImmunityBio’s stock. Investors should approach the recent dip cautiously, as the heightened regulatory scrutiny may lead to further fluctuations in share price amid ongoing developments in the company’s drug efficacy claims.

Source: fool.com